Fulcrum Therapeutics announced a large-scale restructure after discontinuing development of pociredir, its sickle cell disease candidate, following FDA concerns about risk-benefit in the indication. The company said it will cut 85% of roles, reducing its workforce to nine full-time employees. The move follows meetings with the FDA where the regulator highlighted an unexpectedly high rate of secondary hematologic malignancies observed in patients treated with Ipsen’s Tazverik, a PRC2 inhibitor with a similar mechanism. Fulcrum said the FDA’s conclusion left no viable regulatory path forward. Fulcrum is now seeking strategic alternatives, underscoring how safety signals tied to class effects can rapidly change development and corporate survival planning in smaller biotechs.